@JohnnySins The partnering will not occur until Phase 3 preliminary data is made available. No company with shareholders will take the risks of a buyout unless there is clear evidence that risks have been mitigated. That won't be until 2022. Partnership discussions will certainly be in the works right now, as they take a minimum of 9-12 months (as previously mentioned in the BioPub chats). But to say there will be details of partnership discussions "soon" is both a naive comment and overly hopeful. Delays will continue due to COVID, and heck if the vaccines backfire or enough people don't take them in the US, this could be a multi-year process (3-4yrs) for a partnership/buyout.
I also don't like the tidbits about ISB drug inquiries, COVID distributions, etc. Whether or not they are actually pursuing them, it is extremely early stages for the tech to cross into other drugs when a Phase 3 hasn't yet even been approved, let alone begun. It feels like the company is stretching to keep investor interest/pumping up the SP.
Get us results, give us facts, or give us actual timelines for something substantial AND STICK TO THOSE TIMELINES (aka include a buffer) - don't lead investors on with wild theories and hopes, and consistently miss on previous timelines by quarters or years. Over-promising and under-delivering seems to be a trend with this company since 2017...not sure about before.